Intensive insulin therapy

$11.4 Billion Global Rapid Acting Insulin Market (2021 to 2027) - Industry Analysis Report and Forecasts - ResearchAndMarkets.com

Thursday, July 22, 2021 - 5:01pm

A rapid-acting insulin is considered as an insulin analog created to mimic meal-induced insulin secretion.

Key Points: 
  • A rapid-acting insulin is considered as an insulin analog created to mimic meal-induced insulin secretion.
  • By performing rapid-acting insulin opportunity analysis assessment, higher availability of constant glucose tracking will assist in complex analysis of clinic rapid insulin action which was not earlier feasible.
  • Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine.
  • There is a growing case of diabetes and an increasing geriatric population, which is boosting the regional rapid-acting insulin market.

British Columbia First Province to Cover Dexcom G6 Continuous Glucose Monitoring System for People With Type 1 and Type 2 Diabetes on Intensive Insulin Therapy

Friday, June 11, 2021 - 6:28pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210611005428/en/
    The Dexcom G6 CGM System now covered by BC PharmaCare for people living with diabetes who are on intensive insulin therapy.
  • Diabetes.
  • Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial.
  • Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes.

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Wednesday, May 19, 2021 - 6:00am

The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.

Key Points: 
  • The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.
  • "Controlling an insulin pump and viewing its status via smartphone allows people with diabetes to use a device which is usually close at hand.
  • Using the mySugr Pump Control provides people with diabetes more discretion and simplicity with their everyday insulin pump therapy.
  • Users of the mySugr Pump Control are also able to get support from the mySugr Bolus Calculator, which calculates the needed amount of insulin for meal and correction boluses.

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Wednesday, May 19, 2021 - 6:00am

The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.

Key Points: 
  • The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.
  • "Controlling an insulin pump and viewing its status via smartphone allows people with diabetes to use a device which is usually close at hand.
  • Using the mySugr Pump Control provides people with diabetes more discretion and simplicity with their everyday insulin pump therapy.
  • Users of the mySugr Pump Control are also able to get support from the mySugr Bolus Calculator, which calculates the needed amount of insulin for meal and correction boluses.

Glooko Announces Digital Health Collaboration with Eli Lilly's Connected Insulin Pen Solutions in Global Markets

Thursday, May 6, 2021 - 11:45am

The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.

Key Points: 
  • The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.
  • "Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes.
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.

Roche collaborates with Lilly to support people with diabetes on insulin pen therapy

Thursday, May 6, 2021 - 11:45am

This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.

Key Points: 
  • This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.
  • The time spent on activities that come with insulin therapy blood glucose monitoring, carbohydrate counting, injections, and lifestyle planning can add up to several hours a week," said Marcel Gmuender, Global Head of Roche Diabetes Care.
  • The Tempo Smart Button will attach to Lilly\'s Tempo Pen, a modified version of Lilly\'s existing prefilled, disposable insulin pen.
  • "We are thrilled to work with Roche and mySugr to advance our goal to better support the diabetes community.

Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes

Thursday, May 6, 2021 - 11:45am

"Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.

Key Points: 
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • These solutions may also help address psychological barriers like fear of hypoglycemia that may negatively impact diabetes management.
  • Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases2.
  • These agreements and the Tempo Pen and Tempo Smart Button are part of Lilly\'s current and contemplated connected diabetes solutions and reflect Lilly\'s current beliefs and expectations.

Roche collaborates with Lilly to support people with diabetes on insulin pen therapy

Thursday, May 6, 2021 - 11:45am

This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.

Key Points: 
  • This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.
  • The time spent on activities that come with insulin therapy blood glucose monitoring, carbohydrate counting, injections, and lifestyle planning can add up to several hours a week," said Marcel Gmuender, Global Head of Roche Diabetes Care.
  • The Tempo Smart Button will attach to Lilly\'s Tempo Pen, a modified version of Lilly\'s existing prefilled, disposable insulin pen.
  • "We are thrilled to work with Roche and mySugr to advance our goal to better support the diabetes community.

Glooko Announces Digital Health Collaboration with Eli Lilly's Connected Insulin Pen Solutions in Global Markets

Thursday, May 6, 2021 - 11:45am

The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.

Key Points: 
  • The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.
  • "Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes.
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.

Rapid Acting Insulin Market to Garner $8.92 Bn, Globally, by 2027 at 4.1% CAGR: Allied Market Research

Thursday, April 22, 2021 - 2:00pm

b'PORTLAND, Ore., April 22, 2021 /PRNewswire/ -- Allied Market Research recently published a report, titled, " Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20202027".

Key Points: 
  • b'PORTLAND, Ore., April 22, 2021 /PRNewswire/ -- Allied Market Research recently published a report, titled, " Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20202027".
  • As per the report, the global rapid acting insulin industry was accounted for $7.10 billion in 2019, and is estimated to reach $8.92 billion by 2027, growing at a CAGR of 4.1% from 2020 to 2027.\nRise in availability of continuous glucose monitoring, surge in investments in R&D for human recombinant insulin, and increase in government expenditure on healthcare drive the growth of the global rapid acting insulin market.
  • However, adverse effects associated with use of rapid acting insulin hinder the market growth.
  • However, the global rapid acting insulin market across Asia-Pacific is estimated to register the highest CAGR of 5.8% during the forecast period, owing to westernized lifestyle behaviors and the increased prevalence of obesity.\n'